Login
From:
pmc.ncbi.nlm.nih.gov
(Uncensored)
subscribe
Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023 - PMC
https://pmc.ncbi.nlm.nih.gov/articles/PMC11650513/
links
backlinks
Nuvaxovid became available in Australia from February 2022, a year after the first COVID-19 vaccines. This protein-based vaccine was an alternative for people who had had an adverse event to and/or were hesitant to receive an mRNA or ...
Roast topics
Find topics
Find it!
